Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
Sarasota-based biopharmaceutical company, Silo Pharma, has recently announced a partnership with AmplifyBio to advance the development of their novel intranasal therapeutic, SPC-15, specifically designed for the treatment of post-traumatic stress disorder (PTSD) and anxiety. The collaboration aims to complete a Good Laboratory Practice (GLP) study of SPC-15, further evaluating its efficacy and safety profile.
SPC-15 has shown promising potential as a treatment for PTSD and anxiety, offering a novel drug delivery system through intranasal administration. By targeting these conditions, Silo Pharma aims to address a significant unmet medical need and provide patients with alternative treatment options.
In addition to partnering with AmplifyBio, Silo Pharma has recently made
Comments